


# بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ



HOSSAM MAGHRABY



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HOSSAM MAGHRABY

# جامعة عين شمس


التوثيق الإلكتروني والميكروفيلم  
قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



بعض الوثائق

الأصلية تالفة




HOSSAM MAGHRABY



بالرسالة صفحات

لم ترد بالأصل



HOSSAM MAGHRABY

**PLASMINOGEN ACTIVATOR INHIBITOR AS A MEASURE OF  
REPERFUSION IN**

**Acute myocardial infarction in diabetics**

*Thesis*

BIVIE

Submitted for partial fulfillment for the  
M.D. Degree In Internal Medicine

*By*

*Hassan Hussein Abou Hatab*

M.B., Ch. B.; M. Sc., (Internal Medicine)

*Under Supervision of*

Prof. Dr.

**Ahmed Farag Khalifa**

Prof. of Int. Medicine  
Faculty of Medicine  
Tanta University

Prof. Dr.

**Gehan Mohamed Sheira**


Prof. of Int. Medicine  
Faculty of Medicine  
Tanta University

Prof. Dr.

**Sohir Mohamed Abdel-Haleim**

Prof. of Clinical Pathology  
Faculty of Medicine  
Tanta University

Faculty of Medicine  
Tanta University  
2003



## CONTENTS

INTRODUCTION .	1
REVIEW OF LITRETURE	2
AIM OF THE WORK	96
SUBJECTS AND METHODS	97
RESULTS	104
DISSCUSION	141
SUMARRY AND CONCLUSION	155
REFERENCES	160
APPENDIX	
ARABIC SUMMARY	

## **Acknowledgements**

*Thanks to **ALLAH** the creator of all, for helping me to achieve this work*

*I wish to convey my sincere appreciation and deepest gratitude to my grand **Prof. Dr. AHMED FARAG KHALIFA**. Prof. Of Medicine, Tanta University for his kind supervision. His continues care and generous advice derived from his wide experience were a major factor in the establishment of such work.*

*I am especially grateful to **Prof. GEHAN MOHAMED SHEIRA**. Prof. Of Medicine, Tanta University for the sincere and generous help and fruitful discussion throughout this study.*

*Deepest gratitude to **Prof. Dr. SOHAIR MOHAMED ABDEL-HALEIM** Prof. Of Clinical Pathology, Faculty of Medicine, Tanta University for her kind help and continuous encouragement.*

*I would like to thank **Prof. Dr. ABDEL-MOTTY EL-KABBASH**, Prof. Of Public Health, Faculty of Medicine, Tanta University for the sincere and generous help in finishing the statistics of this study.*

*Lastly sincere appreciation is also extended to everyone who has shared in a way or another in the performance of this work.*

## List of abbreviations

PAI-1 = Plasminogen activator inhibitor 1.

PAI-2 = Plasminogen activator inhibitor 2.

PAI-3 = Plasminogen activator inhibitor 3.

t- PA = Tissue plasminogen activator.

SK = Streptokinase.

Uk = Urokinase.

WHO = World Health Organization.

ADA = American Diabetic Association.

DBP = Diastolic blood pressure.

SBP = Systolyic blood pressure.

INL1 = Interlukin-1

TNF= Tumour Necrosis Factor.

AMI= Acute myocardial infarction.

MI= Myocardial infarction.

ECG= electrocardiogram.

PGI<sub>2</sub>= Prostacyclin.

CPK= Creatine phosphokinase.

CKMB = Cardiac fraction of creatine phosphokinase.

TNI = Troponin I.

TNT= Troponin T.

TNC= Troponin C.

AST= Aspartate transaminase.

LDH = Lactate dehydrogenase.

WPW= Wlof- Parkinsonian White Syndrome.

CCU= Coronary care units.

RVI= Right ventricular infarction.

BBB= Bundle branch block.

MU= Million unit.

APSAC= Anisolyted plasminogen streptokinase complex.

ADP= Adenosine diphosphate.

APTT= Activated partial thromboplastin time.

U= Unit.

PTCA= Percutaneous transluminal coronary angioplasty.

AV= Atrioventricular node.

UK= United Kingdom.

DIC= Dissiminated intravascular coagulation.

r-TPA = Recombinant tissue plasminogen activator.

NY = New York.

USA= United States of America.

HbA<sub>1c</sub> = Glycated haemoglobin.

ACC/ AHA= American College Cardiolog, American Heart Association.

K D a = Kilo Dalton.


G= Guanine.

T= Thiamine.

bp= base pair.

# INTRODUCTION

I  
N  
T  
R  
O  
D  
U  
C  
T  
I  
O  
N



## **INTRODUCTION**

The fibrinolytic capacity of human blood is the result of balance between plasminogen activators and inhibitors. Tissue type plasminogen activator (t- PA) constitutes one physiologically important pathway of plasminogen activation. Evidence is accumulating that t-PA is counter balanced by inhibitor that inhibit both t-PA and urokinase. Decreased fibrinolytic capacity of the blood may result from a decreased level of t-PA or from an increased level of plasminogen activator inhibitor type -1 (PAI-1) <sup>1-3</sup>. Coronary thrombosis plays an important role in most subjects with acute myocardial infarction. <sup>4,5</sup>

Thrombolytic treatment has been shown to reduce mortality and improve left ventricular function when given for acute myocardial infarction <sup>6-7</sup>. However, not all patients treated with a thrombolytic agent successfully reperfuse the thrombosed artery. This could be attributed to high plasminogen activator inhibitor activity. In diabetic patients mortality and morbidity from myocardial infarction are high <sup>8,9</sup>

REVIEW OF LITERATURE

REVIEW OF LITERATURE

